Bioventus enrolled first patients in BONES, the Bioventus Observational Non-interventional EXOGEN® Studies program.
BONES will collect real world data from use of EXOGEN, which uses low-intensity pulsed ultrasound to stimulate the body’s own bone-healing process. The studies will compare incidence of fracture nonunions in patients using EXOGEN vs. patients from a U.S. health insurance claims database who received standard of care alone. The studies will include long and small bones of upper and lower extremities.
BONES’ primary endpoint is the ability of EXOGEN to mitigate risk of a fracture progressing to nonunion in the presence of known risk factors.
EXOGEN is marketed around the world as a bone healing system, and has been used to treat >1 million patients.
Bioventus enrolled first patients in BONES, the Bioventus Observational Non-interventional EXOGEN® Studies program.
BONES will collect real world data from use of EXOGEN, which uses low-intensity pulsed ultrasound to stimulate the body’s own bone-healing process. The studies will compare incidence of fracture nonunions in patients using EXOGEN...
Bioventus enrolled first patients in BONES, the Bioventus Observational Non-interventional EXOGEN® Studies program.
BONES will collect real world data from use of EXOGEN, which uses low-intensity pulsed ultrasound to stimulate the body’s own bone-healing process. The studies will compare incidence of fracture nonunions in patients using EXOGEN vs. patients from a U.S. health insurance claims database who received standard of care alone. The studies will include long and small bones of upper and lower extremities.
BONES’ primary endpoint is the ability of EXOGEN to mitigate risk of a fracture progressing to nonunion in the presence of known risk factors.
EXOGEN is marketed around the world as a bone healing system, and has been used to treat >1 million patients.
Copy to clipboard 
